0001095565 HEALTHSTREAm INC 錯誤 --12-31 Q3 2024 949 781 22,362 19,503 144,894 127,009 56,676 57,095 18,420 16,603 0 0 75,000 75,000 30,415 30,415 30,298 30,298 0.028 0.028 0.028 0.025 0.025 0.025 2024年11月15日 2025年2月4日 5 5 5 0 錯誤 錯誤 錯誤 錯誤 00010955652024-01-012024-09-30 xbrli:股份 00010955652024-10-21 iso4217:美元指數 00010955652024-09-30 00010955652023-12-31 0001095565us-gaap:客戶關聯無形資產成員2024-09-30 0001095565us-gaap:客戶關聯無形資產成員2023-12-31 0001095565us-gaap: 其他無形資產成員2024-09-30 0001095565us-gaap: 其他無形資產成員2023-12-31 iso4217:美元指數xbrli:股份 00010955652024-07-012024-09-30 00010955652023-07-012023-09-30 00010955652023-01-012023-09-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-12-31 0001095565us-gaap:留存收益成員2023-12-31 0001095565us-gaap:其他綜合收益的累計成員2023-12-31 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2024-01-012024-03-31 0001095565us-gaap:留存收益成員2024-01-012024-03-31 0001095565us-gaap:其他綜合收益的累計成員2024-01-012024-03-31 00010955652024-01-012024-03-31 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2024-03-31 0001095565us-gaap:留存收益成員2024-03-31 0001095565us-gaap:其他綜合收益的累計成員2024-03-31 00010955652024-03-31 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2024-04-012024-06-30 0001095565us-gaap:留存收益成員2024-04-012024-06-30 0001095565us-gaap:其他綜合收益的累計成員2024-04-012024-06-30 00010955652024-04-012024-06-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2024-06-30 0001095565us-gaap:留存收益成員2024-06-30 0001095565us-gaap:其他綜合收益的累計成員2024-06-30 00010955652024-06-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2024-07-012024-09-30 0001095565us-gaap:留存收益成員2024-07-012024-09-30 0001095565us-gaap:其他綜合收益的累計成員2024-07-012024-09-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2024-09-30 0001095565us-gaap:留存收益成員2024-09-30 0001095565us-gaap:其他綜合收益的累計成員2024-09-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2022-12-31 0001095565us-gaap:留存收益成員2022-12-31 0001095565us-gaap:其他綜合收益的累計成員2022-12-31 00010955652022-12-31 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-01-012023-03-31 0001095565us-gaap:留存收益成員2023-01-012023-03-31 0001095565us-gaap:其他綜合收益的累計成員2023-01-012023-03-31 00010955652023-01-012023-03-31 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-03-31 0001095565us-gaap:留存收益成員2023-03-31 0001095565us-gaap:其他綜合收益的累計成員2023-03-31 00010955652023-03-31 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-04-012023-06-30 0001095565us-gaap:留存收益成員2023-04-012023-06-30 0001095565us-gaap:其他綜合收益的累計成員2023-04-012023-06-30 00010955652023-04-012023-06-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-06-30 0001095565us-gaap:留存收益成員2023-06-30 0001095565us-gaap:其他綜合收益的累計成員2023-06-30 00010955652023-06-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-07-012023-09-30 0001095565us-gaap:留存收益成員2023-07-012023-09-30 0001095565us-gaap:其他綜合收益的累計成員2023-07-012023-09-30 0001095565美國通用會計原則:普通股,包括額外已付股本的成員2023-09-30 0001095565us-gaap:留存收益成員2023-09-30 0001095565us-gaap:其他綜合收益的累計成員2023-09-30 00010955652023-09-30 0001095565hstm:訂閱服務會員2024-07-012024-09-30 0001095565hstm:訂閱服務會員2023-07-012023-09-30 0001095565hstm:訂閱服務會員2024-01-012024-09-30 0001095565hstm:訂閱服務會員2023-01-012023-09-30 0001095565hstm:專業服務會員2024-07-012024-09-30 0001095565hstm:專業服務會員2023-07-012023-09-30 0001095565hstm:專業服務會員2024-01-012024-09-30 0001095565hstm:專業服務會員2023-01-012023-09-30 xbrli:純形 utr:M 00010955652025-10-012024-09-30 thunderdome:item 0001095565hstm:2024年第1季度紅利會員2024-01-012024-09-30 0001095565hstm:2024年第1季度紅利會員2024-09-30 0001095565hstm:2024年第2季度紅利會員2024-01-012024-09-30 0001095565HSTM:2024年Q2股利會員2024-09-30 0001095565HSTM:2024年Q3股利會員2024-01-012024-09-30 0001095565HSTM:2024年Q3股利會員2024-09-30 0001095565us-gaap:後續事件會員2024-10-212024-10-21 0001095565HSTM:2024年Q4股利會員us-gaap:後續事件會員2024-10-212024-10-21 0001095565美國通用會計原則限制性股票單位累計成員2024-01-012024-09-30 0001095565美國通用會計原則限制性股票單位累計成員2023-01-012023-09-30 0001095565hstm: 基於績效的限制性股票獎勵單位RS我們成員2024-01-012024-09-30 utr:是 0001095565hstm: 基於績效的限制性股票獎勵單位RS我們成員hstm: 二零二四年績效成員2024-01-012024-09-30 0001095565hstm: 基於績效的限制性股票獎勵單位RS我們成員hstm: 不基於2023或2024績效的成員2024-01-012024-09-30 0001095565hstm: 基於績效的限制性股票獎勵單位RS我們成員2023-01-012023-09-30 0001095565hstm: 基於績效的限制性股票獎勵單位RS我們成員hstm: 二零二四表現會員2023-01-012023-09-30 0001095565hstm: 基於表現的受限股票單位RS Us會員hstm: 不基於二零二三或二零二四的表現會員2023-01-012023-09-30 0001095565hstm: 基於表現的受限股票單位RS Us會員2022-01-012022-09-30 0001095565hstm: 基於表現的受限股票單位RS Us會員hstm: 二零二四表現會員2022-01-012022-09-30 0001095565hstm: 基於表現的受限股票單位RS Us會員hstm: 不基於二零二二至二零二三或二零二四的表現會員2022-01-012022-09-30 0001095565美國通用會計準則:銷售成本成員2024-07-012024-09-30 0001095565美國通用會計準則:銷售成本成員2023-07-012023-09-30 0001095565美國通用會計準則:銷售成本成員2024-01-012024-09-30 0001095565美國通用會計準則:銷售成本成員2023-01-012023-09-30 0001095565hstm:產品開發成員2024-07-012024-09-30 0001095565hstm:產品開發成員2023-07-012023-09-30 0001095565hstm:產品開發成員2024-01-012024-09-30 0001095565hstm:產品開發成員2023-01-012023-09-30 0001095565us-gaap:銷售和營銷費用2024-07-012024-09-30 0001095565us-gaap:銷售和營銷費用2023-07-012023-09-30 0001095565us-gaap:銷售和營銷費用2024-01-012024-09-30 0001095565us-gaap:銷售和營銷費用2023-01-012023-09-30 0001095565US-GAAP:一般和管理費用成員2024-07-012024-09-30 0001095565US-GAAP:一般和管理費用成員2023-07-012023-09-30 0001095565US-GAAP:一般和管理費用成員2024-01-012024-09-30 0001095565US-GAAP:一般和管理費用成員2023-01-012023-09-30 0001095565us-gaap:FairValueInputsLevel2Memberus-gaap:美國財政部證券成員2024-09-30 0001095565us-gaap:FairValueInputsLevel2Memberus-gaap:美國財政部證券成員2023-12-31 0001095565us-gaap: 循環信貸設施成員hstm: Truist銀行會員hstm: 第三修正案會員2023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:美國合衆銀行會員hstm:第三修正案成員hstm:搖擺線次級貸款成員2023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:美國合衆銀行會員hstm:第三修正案成員hstm:信用證次級貸款成員2023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist銀行會員hstm:第三修正案會員us-gaap:FederalFundsEffectiveSwapRateMember2023-10-062023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist銀行會員hstm:第三修正案會員us-gaap:擔保隔夜融資利率Sofr會員2023-10-062023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist銀行會員hstm:第三修正案會員srt:最小成員us-gaap: 基本利率成員2023-10-062023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist銀行會員hstm:第三修正案會員srt:最大成員us-gaap:擔保隔夜融資利率Sofr會員2023-10-062023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist 銀行成員srt:最小成員2023-10-062023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist 銀行成員2023-10-062023-10-06 0001095565us-gaap: 循環信貸設施成員hstm:Truist 銀行成員2024-09-30
 


 

美國

證券交易委員會

華盛頓特區20549

 

表格 10-Q

(標記一個)

根據1934年證券交易法第13條或第15(d)條的季度報告

 

截至季度結束2024年9月30日

 

根據證券交易法案第13或15(d)條條文提交的過渡報告

 

委員會文件號碼: 000-27701

 

HealthStream, Inc.

(依憑章程所載的完整登記名稱)

 

田納西州

62-1443555

(依據所在地或其他管轄區)

的註冊地或組織地點)

(國稅局雇主識別號碼)

識別號碼)

  

500 11th Avenue North, Suite 1000,

 

納什維爾, 田納西州

37203

(總部辦公地址)

(郵政編碼)

 

(615) 301-3100

(註冊公司之電話號碼,包括區號)

 

 

每種類別的名稱

交易標的(s)

每個註冊交易所的名稱

普通股(面值 $0.00)

HSTM

納斯達克 全球貨幣選擇市場

 

請勾選以下項目,以判定在過去12個月(或更短期間,該註冊人被要求提交報告)內所有根據1934年證券交易法第13條或第15(d)條要求提供報告的報告是否已經提交,並且該註冊人在過去90天中是否受到提交報告的要求。 ☒  否 ☐

 

在前12個月內(或公司需要提交這些文件的較短時間內),公司是否已通過選中標記表明已閱讀並提交了應根據S-t法規第405條規定(本章第232.405條)提交的所有互動式數據文件? ☒  否 ☐

 

請勾選表示公司是否屬於大型加速檔案申報人、加速檔案申報人、非加速檔案申報人、較小型報告公司或新興成長型公司。請參見《交易所法》第120億2條中「大型加速檔案申報人」、「加速檔案申報人」、「較小型報告公司」和「新興成長型公司」的定義。

 

大型加速歸檔人

  

加速歸檔人

非加速歸檔人

  

小型報告公司

新興成長型企業

    

 

如果是新興成長型企業,在符合任何依據證券交易法第13(a)條所提供的任何新的或修改的財務會計準則的遵循的延伸過渡期方面,是否選擇不使用核准記號進行指示。☐

 

請勾選是否該註冊人是一家殼公司(根據交易所法案第120億2條所定義)。是   否 ☒

 

截至2024年10月21日, 30,414,883公司的普通股股份。

 



 

 

 

指数形成10Q

 

HEALTHSTREAm,INC。

 

   

頁面

數字

參見第一部分以獲取我們的美國GAAP結果的其他詳細信息。

財務資訊

1

项目1。

基本報表

1

 

總合資產負債表(未經核實) 2024年9月30日和2023年12月31日

1

 

未經審計的綜合收益簡明合併損益表 截至2024年9月30日和2023年的三個月和九個月

2

 

未經審計的綜合收益簡明合併損益表 截至2024年和2023年9月30日的三個和九個月

3

 

未經審計的綜合股東權益簡明合併報表 截至2024年和2023年9月30日的三個和九個月

4

 

未經審計的綜合現金流量表 2024年和2023年截至9月30日的九個月

5

 

基本報表註腳(未經審計)

6

项目2。

管理層對財務狀況和營運成果的討論與分析

12

项目3。

有關市場風險的定量和定性披露

19

項目 4。

內部控制及程序

20

第二部分。

其他信息

20

项目1。 法律訴訟 21

项目1A。

風險因素

20

项目2。 股票權益的未註冊銷售和資金用途 21
项目5。 其他信息 21

第6項。

展品

21

 

簽名

22

 

 

 

 

第一部分. 財務資訊

 

项目1。 基本報表

 

HEALTHSTREAm,INC。

簡明合併資產負債表(未經查核)

(以千為單位)

 

  

九月三十日,

  

12月31日,

 
  

2024

  

2023

 

資產

        

流動資產:

        

現金及現金等價物

 $57,489  $40,333 

有價證券

  37,404   30,800 

應收帳款,扣除坏账准备$19.5和$15.1,分别为949 15.1781 於2024年9月30日和2023年12月31日,分別為 

  26,326   34,346 

應收賬款-未開單

  5,350   4,100 

已預付版稅-折舊後淨額

  9,239   10,202 

預付軟體維護及訂閱

  6,677   7,397 

其他預付費用和其他流動資產

  3,163   3,032 

全部流動資產

  145,648   130,210 
         

物業及設備,扣除累計折舊$22,362 15.119,503 於2024年9月30日和2023年12月31日,分別為 

  11,086   13,005 

軟件開發淨額,扣除累計攤銷$144,894 15.1127,009 於2024年9月30日和2023年12月31日,分別為 

  42,472   40,643 

租賃用權資產淨額

  18,172   20,114 

商譽

  191,139   191,379 

與客戶關係相關之無形資產淨額,扣除累計攤銷$56,676 15.157,095 於2024年9月30日和2023年12月31日,分別為 

  48,700   54,742 

其他無形資產,減去累積攤提$的淨額為18,420 15.116,603 於2024年9月30日和2023年12月31日,分別為 

  9,269   13,289 

推延佣金

  31,777   31,700 

非流通股權投資

  3,984   4,134 

其他資產

  584   726 

資產總額

 $502,831  $499,942 
         

負債和股東權益

        

流動負債:

        

應付賬款

 $4,444  $7,465 

應計費用

  17,367   22,717 

應計權利金

  5,822   4,556 

逐步認列的收入

  82,939   83,623 

流動負債合計

  110,572   118,361 
         

递延所得税负债

  15,177   16,132 

递延收入,非流动部分

  1,671   2,169 

非流動經營租賃負債

  17,944   20,247 

其他長期負債

  1,986   2,281 
         

股東權益:

        

普通股, 每股面額為 75,000 授權股份為 30,41530,298 2024年9月30日和2023年12月31日分別發行並流通的股份

  251,428   249,075 

保留收益

  104,937   92,368 

累積其他全面損失

  (884)  (691)

股東權益總額

  355,481   340,752 

負債總額及股東權益

 $502,831  $499,942 

 

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

 

 

1

 

 

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(In thousands, except per share data)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30, 2024

   

September 30, 2023

   

September 30, 2024

   

September 30, 2023

 

Revenues, net

  $ 73,095     $ 70,339     $ 217,411     $ 208,482  

Operating costs and expenses:

                               

Cost of revenues (excluding depreciation and amortization)

    24,470       23,587       72,825       71,010  

Product development

    12,100       10,901       36,208       33,610  

Sales and marketing

    11,497       11,290       34,676       34,324  

Other general and administrative expenses

    8,457       9,295       26,325       27,223  

Depreciation and amortization

    10,073       10,403       30,779       30,550  

Total operating costs and expenses

    66,597       65,476       200,813       196,717  
                                 

Operating income

    6,498       4,863       16,598       11,765  
                                 

Other income, net

    981       590       2,722       1,329  
                                 

Income before income tax provision

    7,479       5,453       19,320       13,094  

Income tax provision

    1,754       1,586       4,202       2,471  

Net income

  $ 5,725     $ 3,867     $ 15,118     $ 10,623  
                                 

Net income per share:

                               

Basic

  $ 0.19     $ 0.13     $ 0.50     $ 0.35  

Diluted

  $ 0.19     $ 0.13     $ 0.50     $ 0.35  
                                 

Weighted average shares of common stock outstanding:

                               

Basic

    30,409       30,683       30,374       30,653  

Diluted

    30,590       30,769       30,512       30,734  

Dividends declared per share

  $ 0.028     $ 0.025     $ 0.084     $ 0.075  

 

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

 

2

 

 

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(In thousands)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30, 2024

   

September 30, 2023

   

September 30, 2024

   

September 30, 2023

 

Net income

  $ 5,725     $ 3,867     $ 15,118     $ 10,623  
                                 

Other comprehensive income (loss), net of taxes:

                               

Foreign currency translation adjustments

    290       (371 )     (229 )     (227 )

Unrealized gain (loss) on marketable securities

    43       21       36       (31 )

Total other comprehensive income (loss)

    333       (350 )     (193 )     (258 )

Comprehensive income

  $ 6,058     $ 3,517     $ 14,925     $ 10,365  

 

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

 

3

 

 

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)

(In thousands, except per share data)
 

  

Nine Months Ended September 30, 2024

 
  

Common Stock

  

Retained

  

Accumulated Other Comprehensive

  

Total Shareholders’

 
  

Shares

  

Amount

  

Earnings

  

(Loss)/Income

  

Equity

 

Balance at December 31, 2023

  30,298  $249,075  $92,368  $(691) $340,752 

Net income

        5,227      5,227 

Comprehensive loss

           (481)  (481)

Dividends declared on common stock ($0.028 per share)

        (849)     (849)

Stock-based compensation

     1,060         1,060 

Common stock issued under stock plans, net of shares withheld for employee taxes

  100   (855)        (855)

Balance at March 31, 2024

  30,398  $249,280  $96,746  $(1,172) $344,854 

Net income

        4,168      4,168 

Comprehensive loss

           (45)  (45)

Dividends declared on common stock ($0.028 per share)

        (851)     (851)

Stock-based compensation

     1,094         1,094 

Common stock issued under stock plans, net of shares withheld for employee taxes

  10   (6)        (6)

Balance at June 30, 2024

  30,408  $250,368  $100,063  $(1,217) $349,214 

Net income

        5,725      5,725 

Comprehensive income

           333   333 

Dividends declared on common stock ($0.028 per share)

        (851)     (851)

Stock-based compensation

     1,131         1,131 

Common stock issued under stock plans, net of shares withheld for employee taxes

  7   (71)        (71)

Balance at September 30, 2024

  30,415  $251,428  $104,937  $(884) $355,481 

 

  

Nine Months Ended September 30, 2023

 
  

Common Stock

  

Retained

  

Accumulated Other Comprehensive

  

Total Shareholders’

 
  

Shares

  

Amount

  

Earnings

  

(Loss)/Income

  

Equity

 

Balance at December 31, 2022

  30,579  $254,832  $80,213  $(981) $334,064 

Net income

        2,623      2,623 

Comprehensive loss

           (35)  (35)

Dividends declared on common stock ($0.025 per share)

        (767)     (767)

Stock-based compensation

     945         945 

Common stock issued under stock plans, net of shares withheld for employee taxes

  103   (791)        (791)

Balance at March 31, 2023

  30,682  $254,986  $82,069  $(1,016) $336,039 

Net income

        4,133      4,133 

Comprehensive income

           127   127 

Dividends declared on common stock ($0.025 per share)

        (767)     (767)

Stock-based compensation

     1,093         1,093 

Common stock issued under stock plans, net of shares withheld for employee taxes

  4   (6)        (6)

Balance at June 30, 2023

  30,686  $256,073  $85,435  $(889) $340,619 

Net income

        3,867      3,867 

Comprehensive loss

           (350)  (350)

Dividends declared on common stock ($0.025 per share)

        (767)     (767)

Stock-based compensation

     1,038         1,038 

Common stock issued under stock plans, net of shares withheld for employee taxes

  3   (20)        (20)

Repurchase of common stock

  (99)  (2,141)        (2,141)

Balance at September 30, 2023

  30,590  $254,950  $88,535  $(1,239) $342,246 

 

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

 

4

 

 

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)

 

   

Nine Months Ended September 30,

 
   

2024

   

2023

 

OPERATING ACTIVITIES:

               

Net income

  $ 15,118     $ 10,623  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation and amortization

    30,779       30,550  

Stock-based compensation

    3,285       3,076  

Amortization of deferred commissions

    9,060       8,467  

Provision for credit losses

    2,027       675  

Deferred income taxes

    (960 )     (2,634 )

Loss on equity method investments

    150       330  

Change in fair value of non-marketable equity investments

          (45 )

Other

    (1,205 )     (603 )

Changes in operating assets and liabilities:

               

Accounts and unbilled receivables

    4,744       7,230  

Prepaid royalties

    962       (1,684 )

Other prepaid expenses and other current assets

    (177 )     (817 )

Deferred commissions

    (9,138 )     (9,583 )

Other assets

    143       336  

Accounts payable and accrued expenses

    (8,371 )     (736 )

Accrued royalties

    1,266       1,419  

Deferred revenue

    (1,183 )     3,554  

Net cash provided by operating activities

    46,500       50,158  
                 

INVESTING ACTIVITIES:

               

Business combinations, net of cash acquired

          (6,621 )

Proceeds from maturities of marketable securities

    46,170       19,000  

Purchases of marketable securities

    (51,531 )     (38,235 )

Proceeds from sale of non-marketable equity investments

    765       45  

Payments associated with capitalized software development

    (20,107 )     (19,552 )

Purchases of property and equipment

    (1,198 )     (1,854 )

Net cash used in investing activities

    (25,901 )     (47,217 )
                 

FINANCING ACTIVITIES:

               

Taxes paid related to net settlement of equity awards

    (932 )     (817 )

Repurchases of common stock

          (1,648 )

Payment of cash dividends

    (2,551 )     (2,301 )

Net cash used in financing activities

    (3,483 )     (4,766 )
                 

Effect of exchange rate changes on cash and cash equivalents

    40       (75 )

Net increase (decrease) in cash and cash equivalents

    17,156       (1,900 )

Cash and cash equivalents at beginning of period

    40,333       46,023  

Cash and cash equivalents at end of period

  $ 57,489     $ 44,123  

 

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

 

5

 

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

1. OVERVIEW AND BASIS OF PRESENTATION

 

Company Overview

 

HealthStream provides primarily Software-as-a-Service ("SaaS") based applications for healthcare organizations—all designed to improve business and clinical outcomes by supporting the people who deliver patient care. The Company is focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. The Company also provides its solutions to nursing schools and nursing students.

 

The Company is organized and operated according to its One HealthStream approach, with its hStream technology platform at the center of that approach. Increasingly, SaaS-based applications in the Company's diverse ecosystem of solutions utilize the Company's proprietary hStream technology platform to enhance the value proposition for customers by creating interoperability with and among other applications. As used in this Quarterly Report on Form 10-Q (“Form 10-Q”), “HealthStream,” “Company,” “we,” “us,” and “our” mean HealthStream, Inc. and its subsidiaries, unless the context indicates otherwise.

 

Basis of Presentation

 

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S‑X. Accordingly, condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated in consolidation. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

 

The Condensed Consolidated Balance Sheet at December 31, 2023 was derived from the audited Consolidated Financial Statements at that date but does not include all of the information and footnotes required by US GAAP for a complete set of financial statements. For further information, refer to the Consolidated Financial Statements and Notes thereto for the year ended December 31, 2023 (included in the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 26, 2024).

 

2. RECENT ACCOUNTING PRONOUNCEMENTS

 

In  November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new guidance requires disclosures of significant reportable segment expenses that are regularly provided to the chief operating decision maker and other segment items on an interim and annual basis. Entities with a single reportable segment will also be required to apply the disclosure requirements in ASU 2023-07 on an interim and annual basis. ASU 2023-07 will be effective for the Company for annual periods beginning after  December 15, 2023 and interim periods within fiscal years beginning after  December 15, 2024. The Company is currently evaluating the standard; however, it is not expected to have a material impact on the Company's financial statements.

 

In  December 2023, FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to provide disclosure of disaggregated information in the entity’s tax rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after  December 15, 2024. The Company is currently evaluating the standard; however, it is not expected to have a material impact on the Company's financial statements.

 

6

 

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

3. REVENUE RECOGNITION AND SALES COMMISSIONS

 

Revenue Recognition

 

Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:

 

 

Identification of the contract with a customer

 

Identification of the performance obligations in the contract

 

Determination of the transaction price

 

Allocation of the transaction price to the performance obligations in the contract

 

Recognition of revenue when, or as, the Company satisfies a performance obligation

 

The following table represents revenues disaggregated by revenue source (in thousands). Sales taxes are excluded from revenues.

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2024

  

2023

  

2024

  

2023

 

Subscription services

 $69,918  $67,473  $209,136  $199,993 

Professional services

  3,177   2,866   8,275   8,489 

Total revenues, net

 $73,095  $70,339  $217,411  $208,482 

 

 
For the  three months ended September 30, 2024 and 2023, the Company recognized  $0.2 million and  $0.3 million in impairment losses on receivables and contract assets arising from the Company's contracts with customers, respectively. For the nine months ended September 30, 2024 and 2023, the Company recognized $2.0 million and $0.7 million in impairment losses on receivables and contract assets arising from the Company's contracts with customers, respectively.

 

During the three months ended  September 30, 2024 and 2023, the Company recognized revenues of $45.0 million and $42.2 million, respectively, from amounts included in deferred revenue at the beginning of the respective periods. During the nine months ended September 30, 2024 and 2023, the Company recognized revenues of $79.4 million and $76.0 million, respectively, from amounts included in deferred revenue at the beginning of the respective periods. As of September 30, 2024, approximately $549 million of revenue is expected to be recognized from remaining performance obligations under contracts with customers. The Company expects to recognize revenue related to approximately 43% of these remaining performance obligations over the next 12 months, with the remaining amounts recognized thereafter.

 

Sales Commissions

 

Sales commissions earned by the Company's sales employees are considered incremental and recoverable costs of obtaining a contract with a customer. The Company recorded amortization of deferred commissions of $3.1 million and $3.0 million for the three months ended September 30, 2024 and 2023, respectively, and $9.1 million and $8.5 million for the nine months ended September 30, 2024 and 2023, respectively, which is included in sales and marketing expenses in the accompanying Condensed Consolidated Statements of Income.

 

7

 

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

4. INCOME TAXES

 

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income.

 

The Company computes its interim period provision for income taxes by applying the estimated annual effective tax rate to year-to-date pretax income or loss and adjusts the provision for discrete tax items recorded in the period. During the three months ended September 30, 2024 and 2023, the Company recorded a provision for income taxes of $1.8 million and $1.6 million, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded a provision for income taxes of $4.2 million and $2.5 million, respectively.

 

The Company’s effective tax rate was 22% and 19% for the nine months ended September 30, 2024 and 2023, respectively. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items. The Company recognizes excess tax benefits and tax deficiencies associated with stock-based awards as a component of its provision for income taxes. During the nine months ended September 30, 2024, the Company recorded discrete tax expense of $0.1 million, which consisted primarily of discrete tax expense of $0.2 million related to reserves for uncertain tax positions, partially offset by a $0.1 million discrete tax benefit associated with stock-based awards. During the nine months ended September 30, 2023, the Company recorded discrete tax benefits of $0.1 million, which consisted primarily of tax benefits associated with changes in state apportionment rules in Tennessee upon the enactment of the Tennessee Works Tax Act in the amount of $0.6 million, and stock-based awards in the amount of $0.1 million. This tax benefit for the nine months ended September 30, 2023 was partially offset by $0.3 million of discrete tax expense related to reserves for uncertain tax positions and $0.3 million of discrete tax expense associated with the Company merging VerityStream, Inc. ("VerityStream") into HealthStream.

 

5. SHAREHOLDERS EQUITY

 

Dividends on Common Stock

 

During the nine months ended September 30, 2024, the Company's Board of Directors (“Board”) declared the following quarterly dividends under the Company's dividend policy:

 

Dividend Payment DateDividend Declaration Date Dividend Per Share Record Date Cash Outlay 
March 22, 2024February 19, 2024 $0.028 March 11, 2024 $849,000 
May 17, 2024April 22, 2024  0.028 May 6, 2024  851,000 
August 16, 2024July 22, 2024  0.028 August 5, 2024  851,000 
Total dividends  $0.084   $2,551,000 

 

Additionally, on October 21, 2024, the Board declared a quarterly cash dividend of $0.028 per share, payable on November 15, 2024 to holders of record on November 4, 2024

 

Stock-Based Compensation

 

The Company has stock awards outstanding under its 2016 Omnibus Incentive Plan and 2022 Omnibus Incentive Plan. The Company accounts for its stock-based compensation plans using the fair-value based method for costs related to share-based payments, including restricted share units (“RSUs”) and stock options. During the nine months ended September 30, 2024, the Company issued 110,573 RSUs subject to service-based time vesting, with a weighted average grant date fair value of $27.80 per share, measured based on the closing fair market value of the Company's stock on the date of the grant. During the nine months ended September 30, 2023, the Company issued 128,942 RSUs subject to service-based time vesting, with a weighted average grant date fair value of $23.61 per share, measured based on the closing fair market value of the Company’s stock on the date of grant. 

 

8

 

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

During the nine months ended  September 30, 2024, the Company granted 6,100 performance-based RSUs, the vesting of which occurs over a five-year period in increments of 10%, 15%, 20%, 25%, and 30% and is contingent upon continued service and achieving certain performance criteria established by the compensation committee of the Board (the “Compensation Committee”) on an annual basis based on performance in 2024, 2025, 2026, 2027, and 2028, respectively. The performance criteria for the first-year tranche, or 610 of these performance-based RSUs, is based on 2024 adjusted EBITDA. The measurement date for these 610 performance-based RSUs was established during the nine months ended  September 30, 2024 with a weighted average grant date fair value of $28.79 per share, measured based on the closing fair market value of the Company's stock on the date the performance criteria was established. The performance criteria for the remaining 5,490 performance-based RSUs has not yet been determined and will be established on an annual basis in 2025, 2026, 2027, and 2028, as applicable; therefore, the measurement date for these remaining 5,490 performance-based RSUs cannot be determined until the performance criteria have been established. 

 

During the nine months ended  September 30, 2023, the Company granted 138,000 performance-based RSUs, the vesting of which occurs over a five-year period in increments of 15%, 20%, 20%, 20%, and 25% and is contingent upon continued service and achieving certain performance criteria established by the compensation committee of the Board (the “Compensation Committee”) on an annual basis based on performance in 2023, 2024, 2025, 2026, and 2027, respectively. The performance criteria for the second-year tranche, or 27,600 of these performance-based RSUs, is based on 2024 adjusted EBITDA. The measurement date for these 27,600 performance-based RSUs was established during the nine months ended September 30, 2024 with a weighted average grant date fair value of $26.79 per share, measured based on the closing fair market value of the Company's stock on the date the performance criteria was established. The performance criteria for the remaining 89,700 performance-based RSUs has not yet been determined and will be established on an annual basis in 2025, 2026, and 2027, as applicable; therefore, the measurement date for these remaining 89,700 performance-based RSUs cannot be determined until the performance criteria have been established. 

 

During the nine months ended  September 30, 2022, the Company granted 91,042 performance-based RSUs, the vesting of which occurs over a five-year period in increments of 15%, 20%, 20%, 20%, and 25% and is contingent upon continued service and achieving certain performance criteria established by the Compensation Committee on an annual basis based on performance in 2022, 2023, 2024, 2025, and 2026, respectively. The performance criteria and measurement date for the third-year tranche, or 18,211 of these performance-based RSUs, is based on 2024 adjusted EBITDA and was established during the nine months ended  September 30, 2024 with a grant date fair value of $26.79 per share, measured based on the closing fair market value of the Company's stock on the date the performance criteria was established. The performance criteria for the remaining 40,967 performance-based RSUs has not yet been determined and will be established on an annual basis in 2025 and 2026, as applicable; therefore, the measurement date for these remaining 40,967 performance-based RSUs cannot be determined until the performance criteria have been established.

 

Total stock-based compensation expense recognized in the Condensed Consolidated Statements of Income is as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2024

  

2023

  

2024

  

2023

 

Cost of revenues (excluding depreciation and amortization)

 $49  $50  $152  $149 

Product development

  200   188   599   542 

Sales and marketing

  139   131   415   374 

Other general and administrative

  743   669   2,119   2,011 

Total stock-based compensation expense

 $1,131  $1,038  $3,285  $3,076 

 

9

 

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

6. EARNINGS PER SHARE

 

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of potentially dilutive common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and RSUs subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. The total number of common equivalent shares excluded from the calculations of diluted earnings per share, due to their anti-dilutive effect or contingent performance conditions, was approximately 177,000 and 340,000 for the three months ended September 30, 2024 and 2023, respectively, and 169,000 and 278,000 for the nine months ended September 30, 2024 and 2023, respectively.

 

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2024

  

2023

  

2024

  

2023

 

Numerator:

                

Net income

 $5,725  $3,867  $15,118  $10,623 

Denominator:

                

Weighted-average shares outstanding

  30,409   30,683   30,374   30,653 

Effect of dilutive shares

  181   86   138   81 

Weighted-average diluted shares

  30,590   30,769   30,512   30,734 
                 

Net income per share:

                

Basic

 $0.19  $0.13  $0.50  $0.35 

Diluted

 $0.19  $0.13  $0.50  $0.35 

 

 

7. MARKETABLE SECURITIES

 

The fair value of marketable securities, which were all classified as available for sale and which the Company does not intend to sell nor will the Company be required to sell prior to recovery of their amortized cost basis, included the following (in thousands):

 
  

September 30, 2024

 
  

Adjusted Cost

  

Unrealized Gains

  

Unrealized Losses

  

Fair Value

 

Level 2:

                

U.S. treasury securities

 $37,357  $48  $(1) $37,404 

Total

 $37,357  $48  $(1) $37,404 
 
  

December 31, 2023

 
  

Adjusted Cost

  

Unrealized Gains

  

Unrealized Losses

  

Fair Value

 

Level 2:

                

U.S. treasury securities

 $30,791  $10  $(1) $30,800 

Total

 $30,791  $10  $(1) $30,800 

 

The carrying amounts reported in the Condensed Consolidated Balance Sheets approximate fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of September 30, 2024, the Company did not recognize any allowance for credit impairments on its available for sale securities. All investments in marketable securities are classified as current assets on the Condensed Consolidated Balance Sheets because the underlying securities mature within one year from the balance sheet date.

 
10

 

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

8. DEBT

 

Revolving Credit Facility

 

On  October 6, 2023, the Company entered into an Amended and Restated Revolving Credit Agreement (“Revolving Credit Facility”), amending the Revolving Credit Facility dated as of  November 24, 2014, as amended, with certain lenders party thereto from time to time, and Truist, as Administrative Agent for the lenders. Under the Revolving Credit Facility, the Company  may borrow up to $50.0 million, which includes a $5.0 million swingline sub-facility and a $5.0 million letter of credit sub-facility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The Revolving Credit Facility has a maturity date of  October 6, 2026.

 

The Company's obligations under the Revolving Credit Facility are unsecured. In addition, if the Company forms or acquires any domestic subsidiaries, the loans and other obligations under the Revolving Credit Facility will be guaranteed by such domestic subsidiaries.

 

At the Company’s election, the borrowings under the Revolving Credit Facility, other than the swingline loans, bear interest at either (1) a base rate defined as the highest of (a) the rate which the Administrative Agent announces from time to time as its prime lending rate, as in effect from time to time, or (b) the Federal Funds Rate, as in effect from time to time, plus one-half of one percent (0.50%) per annum (any changes in such rates to be effective as of the date of any change in such rate), plus in each case an applicable margin that varies with the company’s funded debt leverage ratio; or (2) a term secured overnight financing rate (“SOFR”) defined as the greater of (a)(i) the forward-looking term rate based on SOFR determined as of the reference time for such interest period with a term equivalent to such interest period plus (ii) a term SOFR adjustment equal to 0.10% per annum and (b) zero, plus, in each case, an applicable margin that varies with the Company’s consolidated total leverage ratio. The Company’s borrowings under the swingline loans bear interest at the base rate plus the applicable margin. The initial applicable margin for base rate loans is 0.50% and the initial applicable margin SOFR loans is 1.50%. The applicable margins will be adjusted quarterly, in each case two (2) business days after the Administrative Agent's receipt of the Company's quarterly financial statements. The Company is also required to pay a commitment fee accruing on the unused revolving commitment, which fee initially is 20 basis points per annum and a letter of credit fee, accruing at a rate per annum equal to the applicable margin for SOFR loans then in effect on the daily average amount of such lender’s letter of credit exposure.

 

Principal is payable in full at maturity on  October 6, 2026, and there are no scheduled principal payments prior to maturity. Interest on base rate loans and swingline loans is payable quarterly in arrears, and interest on SOFR loans is payable at the end of each interest period, and in the case of interest periods longer than three months, on each day which occurs every three months after the initial date of such interest period.

 

The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Amended and Restated Revolving Credit Agreement), and for stock repurchase and/or redemption transactions that the Company  may authorize.

 

In addition, the Revolving Credit Facility required the Company to meet certain financial tests, including, without limitation:

 

a funded debt leverage ratio (consolidated debt/consolidated EBITDA) of not greater than 3.0 to 1.0; and

 

an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of not less than 3.0 to 1.0.

 

In addition, the Revolving Credit Facility contains certain customary affirmative and negative covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company’s business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.

 

As of September 30, 2024, the Company was in compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of or during the three and nine months ended September 30, 2024.

 

 

11

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Special Cautionary Notice Regarding ForwardLooking Statements

 

You should read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and related Notes included elsewhere in this Form 10-Q and our audited Consolidated Financial Statements and the Notes thereto for the year ended December 31, 2023, appearing in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on February 26, 2024 (the “2023 Form 10-K”). Statements contained in this Form 10-Q that are not historical facts are forward-looking statements that the Company intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend on or refer to future events or conditions, or that include words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions are forward-looking statements.

 

The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

 

In evaluating any forward-looking statement, you should specifically consider the information regarding forward-looking statements set forth above and the risks set forth under the caption Part I, Item 1A. Risk Factors in our 2023 Form 10-K and other disclosures in our 2023 Form 10-K, earnings releases, and other filings with the SEC from time to time, as well as other cautionary statements contained elsewhere in this Form 10-Q, including our critical accounting policies and estimates as discussed in this Form 10-Q and our 2023 Form 10-K. We undertake no obligation to update or revise any forward-looking statements. You should read this Form 10-Q and the documents that we reference in this Form 10-Q and have filed as exhibits to this Form 10-Q completely and with the understanding that our actual future results may be materially different from what we currently expect.

 

Business Overview

 

HealthStream provides primarily SaaS based applications for healthcare organizations—all designed to improve business and clinical outcomes by supporting the people who deliver patient care. We are focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. We also provide our solutions to nursing schools and nursing students.

 

Our business is managed and organized around a single platform strategy, also referred to as our One HealthStream approach. At the center of this single platform strategy is our hStream technology platform. By enabling our applications through hStream, we believe that stand-alone applications, which already provide a powerful value proposition on their own, are beginning to leverage each other to more efficiently and effectively empower our customers to manage their business and improve their outcomes. Further, the Company’s internal structure and executive leadership are likewise shaped by the organizing principle of a single platform, including with regard to technology, operations, accounting, internal reporting (including the nature of information reviewed by our key decision makers), organizational structure, compensation, performance assessment, and resource allocation.

 

Significant financial metrics for the third quarter of 2024 are set forth in the bullets below.

 

Revenues of $73.1 million in the third quarter of 2024, up 3.9% from $70.3 million in the third quarter of 2023

 

Operating income of $6.5 million in the third quarter of 2024, up 33.6% from $4.9 million in the third quarter of 2023

 

Net income of $5.7 million in the third quarter of 2024, up 48.0% from $3.9 million in the third quarter of 2023

 

Earnings per share (“EPS”) of $0.19 per share (diluted) in the third quarter of 2024, up from $0.13 per share (diluted) in the third quarter of 2023

 

Adjusted EBITDA1 of $17.7 million in the third quarter of 2024, up 9.0% from $16.2 million in the third quarter of 2023

 

1

Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this Form 10-Q.

 

12

 

Recent Developments

 

Macroeconomic conditions in the U.S. continue to be challenging in various respects, including as the result of inflationary pressures, interest rate levels, which, despite recent declines, remain elevated, and uncertain geopolitical conditions. In this regard, we have experienced in certain recent periods, and believe that many of our customers have experienced, increased labor, supply chain, capital, and other expenditures associated with inflationary conditions. These conditions impacting the U.S. economy and our customers in the healthcare industry have adversely affected, and may continue to adversely impact, our business and results of operations.

 

While the COVID-19 pandemic continues to cause some level of uncertainty, the impact of the pandemic itself on public health and economic conditions has significantly lessened and normalized to the point of reaching an endemic stage. As our business is focused on providing solutions to healthcare organizations, we continue to closely monitor any developments related to COVID-19 or other public health related events and remain prepared to modify our operating approaches to address COVID 19-related developments or other public health related events as they may arise.

 

Key Financial Metrics

 

Our management utilizes the following financial metrics in connection with managing our business.

 

 

Revenues, net. Revenues, net, reflect income generated by the sales of goods and services related to our operations and, for businesses acquired prior to the adoption of ASU 2021-08 on January 1, 2022, reflects deferred revenue write-downs associated with fair value accounting for such acquired businesses. Revenues, net, were $73.1 million and $217.4 million for the three and nine months ended September 30, 2024, respectively, compared to $70.3 million and $208.5 million for the three and nine months ended September 30, 2023, respectively. Management utilizes revenue in connection with managing our business and believes that this metric provides useful information to investors as a key indicator of the growth and success of our products.

 

 

Net Income. Net income represents revenues, net, less all expenses. Net income was $5.7 million and $15.1 million for the three and nine months ended September 30, 2024, respectively, compared to $3.9 million and $10.6 million for the three and nine months ended September 30, 2023. Management utilizes net income in connection with managing our business, including with regard to our capital deployment strategies.

 

 

Adjusted EBITDA. Adjusted EBITDA, calculated as set forth below under “Reconciliation of Non-GAAP Financial Measures,” is utilized by our management in connection with managing our business and provides useful information to investors because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items, as more specifically set forth below, which may not fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operations. Additionally, certain short-term cash incentive bonuses and performance-based equity award grants are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets. Adjusted EBITDA was $17.7 million and $50.6 million for the three and nine months ended September 30, 2024, respectively, compared to $16.2 million and $45.3 million for the three and nine months ended September 30, 2023, respectively.

 

 

Capital Expenditures. Capital expenditures represent cash payments incurred for purchases of property and equipment and during the development phase for projects to develop software and content. Capital expenditures were $6.8 million and $21.3 million for the three and nine months ended September 30, 2024, respectively, compared to $6.7 million and $21.4 million for the three and nine months ended September 30, 2023, respectively. Management utilizes this metric in connection with managing the allocation of capitalized expenditures in which the Company invests related to the development of its products and believes that this metric is a key indicator of investment in products relative to their current and expected performance.

 

13

 

Critical Accounting Policies and Estimates

 

The Company’s Condensed Consolidated Financial Statements are prepared in accordance with US GAAP. These accounting principles require us to make certain estimates, judgments, and assumptions during the preparation of our Condensed Consolidated Financial Statements. We believe the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time they are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the Condensed Consolidated Financial Statements, as well as the reported amounts of revenues and expenses during the periods presented and related disclosures. To the extent there are material differences between these estimates, judgments, or assumptions and actual results, our Condensed Consolidated Financial Statements will be affected.

 

The accounting policies and estimates that we believe are the most critical in fully understanding and evaluating our reported financial results include the following:

 

 

Revenue recognition

 

 

Accounting for income taxes

 

 

Goodwill

 

In many cases, the accounting treatment of a particular transaction is specifically dictated by US GAAP and does not require management’s judgment in its application. There are also areas where management’s judgment in selecting among available alternatives would not produce a materially different result. See Notes to the Consolidated Financial Statements in our 2023 Form 10-K and the Notes to the Condensed Consolidated Financial Statements herein which contain additional information regarding our accounting policies and other disclosures required by US GAAP. There have been no changes in our critical accounting policies and estimates from those reported in our 2023 Form 10-K.

 

Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023

 

Revenues, net. Revenues increased $2.8 million, or 4%, to $73.1 million for the three months ended September 30, 2024 from $70.3 million for the three months ended September 30, 2023. Subscription revenues increased $2.5 million, or 4%, and professional services revenues increased by $0.3 million, or 11%, compared to the third quarter of 2023. The increase in professional services revenues is primarily due to a one-time payment as a result of a customer acquisition.

 

A comparison of revenues by revenue source is as follows (in thousands):

 

   

Three Months Ended September 30,

 
   

2024

   

2023

   

Percentage Change

 

Subscription services

  $ 69,918     $ 67,473       4 %

Professional services

    3,177       2,866       11 %

Total revenues, net

  $ 73,095     $ 70,339       4 %
                         

% of Revenues

                       

Subscription services

    96 %     96 %        

Professional services

    4 %     4 %        

 

Cost of Revenues (excluding Depreciation and Amortization). Cost of revenues increased $0.9 million, or 4%, to $24.5 million for the three months ended September 30, 2024, from $23.6 million for the three months ended September 30, 2023. Cost of revenues as a percentage of revenues were 33% and 34% for the three months ended September 30, 2024 and 2023, respectively. The increase in expense is primarily associated with higher costs for software and cloud hosting as well as an increase in labor costs and royalties.

 

Product Development. Product development expenses increased $1.2 million, or 11%, to $12.1 million for the three months ended September 30, 2024, from $10.9 million for the three months ended September 30, 2023. Product development expenses as a percentage of revenues were 17% and 15% for the three months ended September 30, 2024 and 2023, respectively. The increase is primarily due to an increase in labor costs, partially offset by an increase in capitalized labor associated with software development activities.

 

Sales and Marketing. Sales and marketing expenses, including personnel costs, increased $0.2 million, or 2%, to $11.5 million for the three months ended September 30, 2024, from $11.3 million for the three months ended September 30, 2023. Sales and marketing expenses were 16% of revenues for both the three months ended September 30, 2024 and 2023. The increase in expense is primarily due to increases in commissions and software expense, which were partially offset by a decrease in labor costs.

 

Other General and Administrative Expenses. Other general and administrative expenses decreased $0.8 million, or 9%, to $8.5 million for the three months ended September 30, 2024, from $9.3 million for the three months ended September 30, 2023. Other general and administrative expenses were 12% and 13% of revenues for the three months ended September 30, 2024 and 2023, respectively. The decrease is primarily due to a $0.4 million recovery of sales taxes from prior software expense payments, partially offset by increased share-based compensation.

 

14

 

Depreciation and Amortization. Depreciation and amortization expense decreased $0.3 million, or 3%, to $10.1 million for the three months ended September 30, 2024, from $10.4 million for the three months ended September 30, 2023. This decrease is primarily a result of a decrease in amortization associated with capitalized software resulting from the recovery of sales taxes from prior capitalized payments related to contract labor associated with software development activities. 

 

Other Income, Net. Other income, net was $1.0 million for the three months ended September 30, 2024, compared to $0.6 million for the three months ended September 30, 2023. The increase is primarily the result of an increase in interest income earned on cash and investments during the three months ended September 30, 2024. 

 

Income Tax Provision. The Company recorded a provision for income taxes of $1.8 million for the three months ended September 30, 2024, compared to $1.6 million for the three months ended September 30, 2023. The Company’s effective tax rate was 23% for the three months ended September 30, 2024, compared to 29% for the three months ended September 30, 2023. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items. During the three months ended September 30, 2024, the Company recorded discrete tax expense of $88,000, which consisted primarily of discrete tax expense related to reserves for uncertain tax positions. During the three months ended September 30, 2023, the Company recorded discrete tax expense of $0.5 million, which consisted primarily of tax expense in the amount of $0.3 million resulting from the impact of merging VerityStream into HealthStream and $0.1 million related to reserves for uncertain tax positions. 

 

Net Income. Net income was $5.7 million and $3.9 million for the three months ended September 30, 2024 and 2023, respectively. EPS was $0.19 per share (diluted) and $0.13 per share (diluted) for the three months ended September 30, 2024 and 2023, respectively.

 

Adjusted EBITDA was $17.7 million for the three months ended September 30, 2024, compared to $16.2 million for the three months ended September 30, 2023. See “Reconciliation of Non-GAAP Financial Measures” below for our reconciliation of adjusted EBITDA to the most directly comparable measure under US GAAP and disclosure regarding why we believe adjusted EBITDA provides useful information to investors.

 

Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023

 

Revenues, net. Revenues increased $8.9 million, or 4%, to $217.4 million for the nine months ended September 30, 2024 from $208.5 million for the nine months ended September 30, 2023. Subscription revenues increased $9.1 million, or 5%, but were partially offset by $0.2 million of declines from professional services revenues.

 

A comparison of revenues by revenue source is as follows (in thousands):

 

   

Nine Months Ended September 30,

 
   

2024

   

2023

   

Percentage Change

 

Subscription services

  $ 209,136     $ 199,993       5 %

Professional services

    8,275       8,489       -3 %

Total revenues, net

  $ 217,411     $ 208,482       4 %
                         

% of Revenues

                       

Subscription services

    96 %     96 %        

Professional services

    4 %     4 %        

 

Cost of Revenues (excluding Depreciation and Amortization). Cost of revenues increased $1.8 million, or 3%, to $72.8 million for the nine months ended September 30, 2024, from $71.0 million for the nine months ended September 30, 2023. Cost of revenues as a percentage of revenues were 33% and 34% the nine months ended September 30, 2024 and 2023, respectively. The increase in expense is primarily associated with higher software expenses and cloud hosting costs, partially offset by lower labor costs. Labor costs recognized during the nine months ended September 30, 2023 included severance costs incurred in connection with the Company's previously disclosed restructuring under a single platform strategy. 

 

Product Development. Product development expenses increased $2.6 million, or 8%, to $36.2 million for the nine months ended September 30, 2024, from $33.6 million for the nine months ended September 30, 2023. Product development expenses as a percentage of revenues were 17% and 16% for the nine months ended September 30, 2024 and 2023, respectively. The increase is primarily due to an increase in labor costs, partially offset by an increase in capitalized labor associated with software development activities.

 

Sales and Marketing. Sales and marketing expenses, including personnel costs, increased $0.4 million, or 1%, to $34.7 million for the nine months ended September 30, 2024, from $34.3 million for the nine months ended September 30, 2023. Sales and marketing expenses were 16% of revenues for both the nine months ended September 30, 2024 and 2023. The increase in expense is primarily due to increases in general marketing expenses, commissions, and travel expenses, which were partially offset by a decrease in labor costs.

 

Other General and Administrative Expenses. Other general and administrative expenses decreased $0.9 million, or 3%, to $26.3 million for the nine months ended September 30, 2024, from $27.2 million for the nine months ended September 30, 2023. Other general and administrative expenses were 12% and 13% of revenues for the nine months ended September 30, 2024 and 2023, respectively. The decrease is primarily due to lower labor costs, professional service fees, and a $0.4 million recovery of sales taxes from prior software expense payments, which were partially offset by an increase in bad debt expense of $1.4 million, which was primarily associated with a single-customer bankruptcy.

 

15

 

Depreciation and Amortization. Depreciation and amortization expense increased $0.2 million, or 1%, to $30.8 million for the nine months ended September 30, 2024, from $30.6 million for the nine months ended September 30, 2023. This increase is primarily a result of an increase in amortization associated with capitalized software.

 

Other Income, Net. Other income, net was $2.7 million for the nine months ended September 30, 2024, compared to $1.3 million for the nine months ended September 30, 2023. The increase is primarily the result of an increase in interest income earned on cash and investments during the nine months ended September 30, 2024. 

 

Income Tax Provision. The Company recorded a provision for income taxes of $4.2 million for the nine months ended September 30, 2024, compared to $2.5 million for the nine months ended September 30, 2023. The Company’s effective tax rate was 22% for the nine months ended September 30, 2024, compared to 19% for the nine months ended September 30, 2023. The Company’s effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items. During the nine months ended September 30, 2024, the Company recorded discrete tax expense of $0.1 million, which consisted primarily of discrete tax expense of $0.2 million related to reserves for uncertain tax positions, partially offset by a $0.1 million discrete tax benefit associated with stock-based awards. During the nine months ended September 30, 2023, the Company recorded discrete tax benefits of $0.1 million, which consisted primarily of tax benefits in the amount of $0.6 million resulting from changes in state apportionment rules in Tennessee upon the enactment of the Tennessee Works Tax Act and stock-based awards in the amount of $0.1 million. This tax benefit was partially offset by $0.3 million of discrete tax expense related to reserves for uncertain tax positions and $0.3 million of discrete tax expenses related to the impact of merging VerityStream into HealthStream.

 

Net Income. Net income was $15.1 million and $10.6 million for the nine months ended September 30, 2024 and 2023, respectively. EPS was $0.50 per share (diluted) and $0.35 per share (diluted) for the nine months ended September 30, 2024 and 2023, respectively.

 

Adjusted EBITDA was $50.6 million for the nine months ended September 30, 2024, compared to $45.3 million for the nine months ended September 30, 2023. See “Reconciliation of Non-GAAP Financial Measures” below for our reconciliation of adjusted EBITDA to the most directly comparable measure under US GAAP and disclosure regarding why we believe adjusted EBITDA provides useful information to investors.

 

16

 

Reconciliation of Non-GAAP Financial Measures

 

This Form 10-Q presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing our financial results and ongoing operational performance.

 

In order to better assess the Company’s financial results, management believes that net income before interest, income taxes, stock-based compensation, depreciation and amortization, and changes in fair value of, including gains (losses) on the sale of, non-marketable equity investments (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. In addition, as discussed below, for periods ended on or prior to December 31, 2023, adjusted EBITDA excludes the impact of deferred revenue write-downs associated with fair value accounting for acquired businesses. We believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. Additionally, certain short-term cash incentive bonuses and performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.

 

As previously disclosed, prior to the Company early adopting ASU 2021-08 effective January 1, 2022, following the completion of any acquisition by the Company, the Company was required to record the acquired deferred revenue at fair value as defined in GAAP, which typically resulted in a write-down of the acquired deferred revenue. In connection therewith, management determined that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred revenue write-downs associated with fair value accounting for businesses acquired prior to the January 1, 2022 effective date of the Company's adoption of ASU 2021-08 (the “Pre-2022 Acquisitions”) provided useful information to investors because the deferred revenue write-down recognized in periods after any such Pre-2022 Acquisitions could, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance. Following the adoption of ASU 2021-08, contracts acquired in an acquisition completed on or after January 1, 2022 have been measured as if the Company had originated the contract (rather than the contract being measured at fair value) such that, for such acquisitions, the Company no longer records deferred revenue write-downs associated with acquired businesses. With respect to periods ended on or prior to December 31, 2023, the Company has included an adjustment in the calculation of adjusted EBITDA for the impact of deferred revenue write-downs associated with the Pre-2022 Acquisitions consistent with this prior accounting standard, given the ongoing impact of such deferred revenue on the Company's financial results under GAAP over this time period. With respect to periods beginning on and after January 1, 2024, the Company no longer recognizes any deferred revenue write-downs associated with the Pre-2022 Acquisitions under GAAP, and accordingly such deferred revenue write-downs are not an adjustment in connection with the calculation of adjusted EBITDA for periods on and after January 1, 2024.

 

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool. 

 

A reconciliation of adjusted EBITDA to the most directly comparable GAAP measure, net income, is set forth below (in thousands).

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2024

   

2023

   

2024

   

2023

 

GAAP net income

  $ 5,725     $ 3,867     $ 15,118     $ 10,623  

Deferred revenue write-down

          30             128  

Interest income

    (1,007 )     (667 )     (2,856 )     (1,580 )

Interest expense

    26       33       75       99  

Income tax provision

    1,754       1,586       4,202       2,471  

Stock-based compensation expense

    1,131       1,038       3,285       3,076  

Depreciation and amortization

    10,073       10,403       30,779       30,550  

Change in fair value of non-marketable equity investments

          (45 )           (45 )

Adjusted EBITDA

  $ 17,702     $ 16,245     $ 50,603     $ 45,322  

 

17

 

Liquidity and Capital Resources

 

Net cash provided by operating activities decreased by $3.7 million to $46.5 million during the nine months ended September 30, 2024, from $50.2 million during the nine months ended September 30, 2023. The decrease in net cash provided by operating activities is primarily due to a $3.6 million increase in income tax payments, while cash receipts increased modestly compared to the prior year. Our days sales outstanding (“DSO”) was 37 days for the third quarter of 2024 compared to 43 days for the third quarter of 2023. The Company calculates DSO by dividing the average accounts receivable balance for the quarter by average daily revenues for the quarter. The Company’s primary sources of cash were receipts generated from the sales of our products and services. The primary uses of cash to fund operations included personnel expenses, sales commissions, royalty payments, payments for contract labor and other direct expenses associated with delivery of our products and services, income tax payments, and general corporate expenses.

 

Net cash used in investing activities was $25.9 million for the nine months ended September 30, 2024, compared to $47.2 million for the nine months ended September 30, 2023. During the nine months ended September 30, 2024, the Company invested in marketable securities of $51.5 million, made payments for capitalized software development of $20.1 million, and purchased property and equipment of $1.2 million. These uses of cash were partially offset by $46.2 million in maturities of marketable securities and $0.8 million received upon the settlement and release of escrowed proceeds related to a prior sale of a non-marketable equity investment. During the nine months ended September 30, 2023, the Company spent $6.6 million for the acquisition of substantially all of the assets of Electronic Education Documentation System, LLC (“eeds”) (note: the eeds acquisition was consummated on December 31, 2022, but was funded in January 2023 such that the purchase price for eeds impacted net cash used in investing activities during the nine months ended September 30, 2023), invested in marketable securities of $38.2 million, made payments for capitalized software development of $19.6 million, and purchased property and equipment of $1.9 million. These uses of cash were partially offset by $19.0 million in maturities of marketable securities and $45,000 in proceeds from the sales of non-marketable equity investments.

 

Net cash used in financing activities was $3.5 million for the nine months ended September 30, 2024, compared to $4.8 million for the nine months ended September 30, 2023. The uses of cash for the nine months ended September 30, 2024 included $2.6 million for the payment of cash dividends and $0.9 million for the payment of employee payroll taxes in relation to the vesting of restricted share units. The uses of cash for the nine months ended September 30, 2023 included $2.3 million for the payment of cash dividends, $1.6 million for repurchases of common stock (note: share repurchases totaled $2.1 million during the nine months ended September 30, 2023, with $1.6 million paid in cash and $0.5 million included in accrued expenses in the Company's Condensed Consolidated Balance Sheet as of September 30, 2023), and $0.8 million for the payment of employee payroll taxes in relation to the vesting of restricted share units.

 

Our balance sheet reflects working capital of $35.1 million at September 30, 2024, compared to $11.8 million at December 31, 2023. The increase in working capital is primarily a result of an increase in cash and cash equivalents. The Company’s primary source of liquidity as of September 30, 2024 was $57.5 million of cash and cash equivalents and $37.4 million of marketable securities.

 

The Company also has a $50.0 million revolving credit facility. There currently are no outstanding borrowings under the revolving credit facility. The revolving credit facility expires on October 6, 2026, unless earlier renewed or amended. For additional information regarding our revolving credit facility, see Note 8 to the Condensed Consolidated Financial Statements included herein.

 

On September 13, 2023, the Company announced a share repurchase program approved by the Company's Board under which the Company was authorized to purchase up to $10.0 million of the Company's outstanding shares of common stock. The share repurchase program expired according to its terms on March 31, 2024, and no repurchases occurred during the three months ended March 31, 2024. During the term of this program, the Company repurchased a total of 404,188 shares under this program at an aggregate fair value of $8.9 million, based on an average price per share of $22.07 (excluding the cost of broker commissions). We may elect in the future to adopt a new share repurchase program.

 

On February 20, 2023, we announced that our Board approved a quarterly dividend policy. Under this dividend policy, our Board declared, and the Company paid, quarterly cash dividends on our common stock at the rate of $0.025 per share during the year ended December 31, 2023. On February 19, 2024, our Board approved a quarterly dividend under this dividend policy at a rate of $0.028 per share, which was paid on March 22, 2024 to the holders of record of our common stock on March 11, 2024. On April 22, 2024, the Board approved a quarterly cash dividend of $0.028 per share, which was paid on May 17, 2024 to holders of record of our common stock on May 6, 2024. On July 22, 2024, the Board approved a quarterly cash dividend of $0.028 per share, which was paid on August 16, 2024 to holders of record of our common stock on August 5, 2024. On October 21, 2024, the Board approved a quarterly cash dividend of $0.028 per share, which will be payable on November 15, 2024 to holders of record of our common stock on November 4, 2024.
 
The dividend policy and the declaration and payment of each quarterly cash dividend will be subject to our Board’s continuing determination that the policy and the declaration and payment of dividends thereunder are in the best interests of our shareholders and are in compliance with applicable law and our credit agreement. Our Board retains the power to modify, suspend, or cancel the dividend policy and quarterly dividends thereunder in any manner and at any time that our Board may deem necessary or appropriate.
 
We believe that our existing cash and cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development, dividend payments, any repurchases of shares we may elect to make under any future share repurchase program, and capital expenditures for at least the next 12 months and for the foreseeable future thereafter.
 
18

 

In addition, the Company’s growth strategy includes acquiring businesses or making strategic investments in businesses that complement or enhance our business. It is anticipated that future acquisitions or strategic investments, if any, would be effected through cash consideration, stock consideration, or a combination of both. The issuance of our stock as consideration for an acquisition or to raise additional capital could have a dilutive effect on earnings per share and could adversely affect our stock price. Our revolving credit facility contains financial covenants and availability calculations designed to set a maximum leverage ratio of outstanding debt to adjusted EBITDA and an interest coverage ratio of adjusted EBITDA to interest expense. Therefore, the maximum borrowings against our new revolving credit facility would be dependent on the covenant calculations at the time of borrowing. As of September 30, 2024, we were in compliance with all covenants under our revolving credit facility. There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot provide assurance that if we need additional financing that it will be available on terms favorable to us, or at all. Failure to generate sufficient cash flow from operations or raise additional capital when required in sufficient amounts and on terms acceptable to us could harm our business, financial condition, and results of operations.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

The Company is exposed to market risk from changes in interest rates, foreign currency risk, and investment risk. We do not have any commodity price risk.

 

Interest Rate Risk

 

As of September 30, 2024, and during the three months then ended, the Company had no outstanding debt. We may become subject to interest rate market risk associated with any future borrowings under our revolving credit facility. The interest rate under the revolving credit facility varies depending on the interest rate option selected by the Company plus a margin determined in accordance with a pricing grid. We are also exposed to market risk with respect to our cash and investment balances, which were $94.9 million at September 30, 2024. Assuming a hypothetical 10% decrease in interest rates for invested balances, interest income from cash and investments would decrease on an annualized basis by $0.4 million.

 

Foreign Currency Risk

 

We have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the US dollar, including Canadian dollar, New Zealand dollar, and Australian dollar. Increases or decreases in our foreign-denominated revenue from movements in foreign exchange rates are often partially offset by the corresponding increases or decreases in our foreign-denominated operating expenses.

 

To the extent that our international operations grow, our risks associated with fluctuation in currency rates will become greater, and we will continue to assess our approach to managing this risk. In addition, currency fluctuations or a weakening US dollar can increase the costs of our international operations. To date, we have not entered into any foreign currency hedging contracts although we may do so in the future.

 

Investment Risk

 

The Company’s investment policy and strategy is focused on investing in highly rated securities with the objective of minimizing the potential risk of principal loss. The Company’s policy limits the amount of credit exposure to any single issuer and sets limits on the average portfolio maturity.

 

We have an investment portfolio that includes strategic investments in privately held companies, which primarily include early-stage companies. We primarily invest in healthcare technology companies that we believe can help expand our ecosystem. We may continue to make these types of strategic investments as opportunities arise that we find attractive. We may experience additional volatility to our Consolidated Financial Statements due to changes in market prices, observable price changes, and impairments to our strategic investments. These changes could be material based on market conditions and events. 

 

The above market risk discussion and the estimated amounts presented are forward-looking statements of market risk assuming the occurrence of certain adverse market conditions. Actual results in the future may differ materially from those projected as a result of actual developments in the market.

 

19

 

Item 4. Controls and Procedures

 

Evaluation of Controls and Procedures

 

HealthStream’s chief executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this Form 10-Q. Based on that evaluation, the chief executive officer and principal financial officer have concluded that HealthStream’s disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and the information required to be disclosed in the reports the Company files or submits under the Exchange Act was accumulated and communicated to the Company’s management, including its chief executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

There was no change in HealthStream’s internal control over financial reporting that occurred during the third quarter of 2024 that has materially affected, or that is reasonably likely to materially affect, HealthStream’s internal control over financial reporting.

 

PART II ‑ OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

There have been no material changes to the risk factors previously disclosed in Part I, Item 1A of the 2023 Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None. Without limiting the generality of the foregoing, the Company did not have any share repurchase program in effect and did not purchase any shares of common stock of the Company during the three months ended September 30, 2024.

 

Item 5. Other Information

 

None. Without limiting the generality of the foregoing, during the three months ended September 30, 2024, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement,” or any “non-Rule 10b-5 trading arrangement,” as such terms are defined in Item 408 of Regulation S-K.

 

20

 

 

Item 6. Exhibits

 

 

(a)

Exhibits

 

31.1

Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.1 INS

Inline XBRL Instance Document – The instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.1 SCH

Inline XBRL Taxonomy Extension Schema

101.1 CAL

Inline XBRL Taxonomy Extension Calculation Linkbase

101.1 DEF

Inline XBRL Taxonomy Extension Definition Linkbase

101.1 LAB

Inline XBRL Taxonomy Extension Label Linkbase

101.1 PRE

Inline XBRL Taxonomy Extension Presentation Linkbase

104 The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, has been formatted in Inline XBRL

 

21

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

HEALTHSTREAM, INC.

       
October 24, 2024

By:

 

/s/ Scott A. Roberts

     

Scott A. Roberts

     

Chief Financial Officer

 

 

22